A Randomized, Double-Blind, Placebo-Controlled Phase II Dose-Ranging Study of the OrthoDerm Transdermal Nitroglycerin Patch for Patients With Chronic Lateral Epicondylitis
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Tendonitis
- Sponsor
- Cure Therapeutics
- Enrollment
- 164
- Locations
- 1
- Primary Endpoint
- pain-free grip strength
- Last Updated
- 19 years ago
Overview
Brief Summary
The purpose of the study is to evaluate the effectiveness and safety of the use of low-dose nitroglycerin transdermal patches to treat pain and function in chronic tennis elbow.
Detailed Description
Chronic tendonitis remains difficult to treat. Nitric oxide has been demonstrated to stimulate tenocytes to proliferate, differentiate and produce matrix components including collagen. Studies have demonstrated that nitroglycerin transdermal patches, which release nitric oxide, reduce pain and increase function in patients with chronic tendonitis. The purpose of the present study is to examine the efficacy of three dose levels of nitroglycerin, compared to placebo, in reducing pain and increasing function in patients with chronic (greater than three months' duration) lateral epicondylitis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •males \>18 yr and \< 70 yr
- •BMI \< 38
- •chronic lateral epicondylitis (symptomatic \> 3 mo)
- •pain on provocation \>/- 4 on 11 point scale
Exclusion Criteria
- •patients on other pain medications
- •bilateral elbow pain
- •any humerus elbow or forearm fracture or surgery
- •signs of injury other than lateral epicondylitis
- •any concomitant disease or pain of the upper extremity
- •orthostatic hypotension
- •patients taking MAO inhibitors, phosphodiesterase inhibitors, adrenergic agents
- •pregnant or nursing women
Outcomes
Primary Outcomes
pain-free grip strength
Secondary Outcomes
- pain at rest
- pain on provocation
- function